(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 November 2022 (10.11.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/235842 A1

(51) International Patent Classification:
A61K 31/4245 (2006.01) *A61P 3/10* (2006.01)
A61K 31/444 (2006.01) *A61P 9/00* (2006.01)
A61P 3/00 (2006.01) *A61P 9/12* (2006.01)

(21) International Application Number:
PCT/US2022/027725

(22) International Filing Date:
04 May 2022 (04.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/183,914	04 May 2021 (04.05.2021)	US
63/210,676	15 June 2021 (15.06.2021)	US
63/210,690	15 June 2021 (15.06.2021)	US

(71) Applicant: **TENAYA THERAPEUTICS, INC.** [US/US]; 171 Oyster Point Boulevard, Suite 500, South San Francisco, California 94080 (US).

(72) Inventors: **YANG, Jin**; c/o Tenaya Therapeutics, Inc., 171 Oyster Point Boulevard, Suite 500, South San Francisco, California 94080 (US). **MANDEGAR, Mohammad A.**; c/o Tenaya Therapeutics, Inc., 171 Oyster Point Boulevard, Suite 500, South San Francisco, California 94080 (US). **HOEY, Timothy C.**; c/o Tenaya Therapeutics, Inc., 171 Oyster Point Boulevard, Suite 500, South San Francisco, California 94080 (US).

(74) Agent: **ELBERT, Maya** et al.; COOLEY LLP, 1299 Pennsylvania Avenue NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

WO 2022/235842 A1

(54) Title: 2-FLUOROALKYL-1,3,4-OXADIAZOL-5-YL-THIAZOL, HDAC6 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISEASE AND HFPEF

(57) Abstract: Provided herein are methods of treating or preventing metabolic disease with an HDAC6 inhibitor. Also provided herein are methods of treating or preventing heart failure with preserved ejection fraction with an HDAC6 inhibitor. A variety of HDAC6 inhibitors are described herein for use in treating or preventing metabolic disease or heart failure with preserved ejection fraction. In one aspect, described herein are methods of treating a human patient by orally administering an HDAC6 inhibitor, such as an inhibitor of Formula (I) or Formula (II).